We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exhaled NO Testing in Filariasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01628497
Recruitment Status : Completed
First Posted : June 26, 2012
Last Update Posted : April 7, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study is looking at the difference in exhaled nitric oxide levels in patients with and without laboratory evidence of filariasis.

Condition or disease
Filariasis

Study Design

Study Type : Observational
Actual Enrollment : 96 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Exhaled NO Testing in Filariasis
Study Start Date : May 2012
Primary Completion Date : March 2014
Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Positive filariasis test
Those testing positive for filariasis
Filariasis negative


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Study subjects:

  • recruited from patients with a chief complaint of wheezing, asthma or cough.
  • assessed by a physician prior to consideration for enrollment into the study
  • screened by the study investigator after evaluation by the physician

Control subjects:

Controls will be matched with cases by gender, age and region of residence. They will have non-emergent complaints without respiratory symptoms.

Criteria

Inclusion Criteria:

  1. Age 6 years or older of either gender
  2. Patients presenting with pulmonary symptoms a. Confirmed or suspected asthma patients: i. Patients presenting with symptoms consistent with an acute exacerbation of asthma, including:

1. Wheezing 2. Shortness of breath 3. Chest tightness 4. Cough ii. Disposition to the asthma room after triage and physician evaluation (disposition to other areas of the A&E allowed if due to no available space in the asthma room) iii. Patients are potentially eligible with or without a past history of health care provider diagnosed asthma iv. Patients are potentially eligible regardless of the number of previous episodes of wheezing (i.e. patients with a first episode of bronchospasm are potentially eligible) v. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:

  1. They have a dry cough (no production of purulent sputum)
  2. They have bronchospasm as manifested by wheezing or need for salbutamol (albuterol) breathing treatments vi. Patients with wheezing are not eligible if they:

1. Have purulent sputum production 2. Have known or suspected:

a. Tuberculosis b. Immunodeficiency c. Congestive heart failure d. Foreign body aspiration b. Patients presenting with a chief complaint of cough: i. Potentially eligible patients will have a cough of greater than one week (seven days) duration ii. Asthma room disposition is not required for these subjects iii. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:

1. They have a dry cough (no production of purulent sputum) iv. Patients with cough are not eligible if:

  1. Have purulent sputum production
  2. Have known or suspected:

    1. Tuberculosis
    2. Immunodeficiency
    3. Congestive heart failure
    4. Foreign body aspiration
  3. Patients will be medically stable at the time of the consent process (see exclusion criteria below)
  4. A minimum of 2 years of continuous residence in Guyana at the time of enrollment, exclusive of short trips out of the country (at least 21 of previous 24 months physically in Guyana)
  5. English speaking

Exclusion Criteria:

  1. Patients less than 6 years of age
  2. Patients who do not consent to the study
  3. Children (<18 years) without a parent/guardian present
  4. Prisoners
  5. Patients who appear to be medically or psychologically unstable or felt to be otherwise inappropriate for study enrollment, in the opinion of the investigator or any treating health care provider. This determination will be made on an individual basis, but some of the general criteria to be used in making this determination will be:

    i. The patient appears to be in significant pain ii. The patient appears acutely ill - severe respiratory distress, diaphoretic, altered mental status, active bleeding, actively vomiting, etc.

    iii. Those with respiratory difficulty to the point they cannot speak in complete sentences iv. Chief complaint of sexual assault v. The patient appears acutely intoxicated vi. The patient displays agitated, nervous, restless, or other behavior suggestive of an uncontrolled psychiatric emergency

  6. Patients with pulmonary findings felt to be secondary to congestive heart failure, foreign body, bacterial pneumonia, tuberculosis or other clearly defined cause
  7. Non-English speaking patients
  8. Patients without at least 2 years of residence (exclusive of short trips abroad, total of 21 of 24 previous months physically in Guyana) in Guyana at the time of enrollment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628497


Locations
Guyana
Georgetown Public Hospital Corporation
Georgetown, Region 4, Guyana
Sponsors and Collaborators
Vanderbilt University Medical Center
More Information

Responsible Party: Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT01628497     History of Changes
Other Study ID Numbers: Fil-01
First Posted: June 26, 2012    Key Record Dates
Last Update Posted: April 7, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Filariasis
Elephantiasis
Spirurida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
Lymphedema
Lymphatic Diseases